Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 8/20 | 0.64 |
| ▸ | REN | P00797 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | F2 | P00734 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | PEPD | P12955 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | HRH1 | P35367 | 1/20 | 0.51 |
| ▸ | THPO | P40225 | 1/20 | 0.51 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.51 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7052375 | 1.00 | ACE (0.64) | ACERENLMNAHSD17B10CYP2C19 | |
| SCHEMBL10537366 | 1.00 | ACE (0.64) | ACERENLMNAHSD17B10CYP2C19 | |
| SCHEMBL19024772 | 0.90 | ACE (0.60) | ACERENMAPTACE2 | |
| SCHEMBL11742911 | 0.90 | ACE (0.60) | ACERENMAPTACE2 | |
| SCHEMBL21671042 | 0.89 | ACE (0.50) | ACERENLMNAHSD17B10CYP2C19 | |
| SCHEMBL6782705 | 0.89 | ACE (0.72) | ACEREN | |
| SCHEMBL6782701 | 0.89 | ACE (0.72) | ACEREN | |
| SCHEMBL5035730 | 0.88 | ACE (0.59) | ACERENACE2 | |
| SCHEMBL5033213 | 0.88 | ACE (0.59) | ACERENACE2 | |
| SCHEMBL5035727 | 0.88 | ACE (0.59) | ACERENACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0416282-B1 | Microbiologically produced N-Acyl-L-proline-acylase, process for its production and its use | DEGUSSA (DE) | 1994-09-14 | — | — | EP | claimed |
| EP-0416282-A1 | Microbiologically produced N-Acyl-L-proline-acylase, process for its production and its use | Degussa Aktiengesellschaft (DE) | 1991-03-13 | — | — | EP | claimed |
| US-4859653-A | Use of compositions of matter containing N-acylates of alpha aminoacids for the treatment of skin | MORELLE JEAN V (FR) | 1989-08-22 | — | — | US | claimed |
| CN-120077040-A | Compounds for SHP2 protein degradation and medical uses thereof | 尤比克斯治疗公司 | 2025-05-30 | — | — | CN | disclosed |
| US-20250000948-A1 | SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | ADOCIA (FR) | 2025-01-02 | — | — | US | disclosed |
| EP-4299057-A1 | SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | Adocia (FR) | 2024-01-03 | — | — | EP | disclosed |
| WO-2023084118-A1 | SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | ADOCIA (FR) | 2023-05-19 | — | — | WO | disclosed |
| EP-4180060-A1 | SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | Adocia (FR) | 2023-05-17 | — | — | EP | disclosed |
| US-9782336-B2 | Moisturizer and cosmetic containing same | AJINOMOTO CO., INC. (JP) | 2017-10-10 | — | — | US | disclosed |
| EP-3192493-A1 | MOISTURIZER AND COSMETIC CONTAINING SAME | Ajinomoto Co., Inc. (JP) | 2017-07-19 | — | — | EP | disclosed |
| US-20170181947-A1 | MOISTURIZER AND COSMETIC CONTAINING SAME | AJINOMOTO CO., INC. (JP) | 2017-06-29 | — | — | US | disclosed |
| WO-1999065304-A1 | COMPOSITIONS FOR PROTECTING PLANTS AGAINST OXIDATIVE STRESS | MORELLE JEAN (FR) | 1999-12-23 | — | — | WO | disclosed |
| EP-0784603-A2 | RACEMISATION OF PRECURSORS TO LEVOBUPIVACAINE AND ANALOGUES THEREOF | Chiroscience Limited (GB) | 1997-07-23 | — | — | EP | disclosed |
| WO-1996011173-A2 | RACEMISATION OF PRECURSORS TO LEVOBUPIVACAINE AND ANALOGUES THEREOF | CHIROSCIENCE LIMITED (GB) | 1996-04-18 | — | — | WO | disclosed |
| EP-0416282-A1 | Microbiologically produced N-Acyl-L-proline-acylase, process for its production and its use | Degussa Aktiengesellschaft (DE) | 1991-03-13 | — | — | EP | disclosed |
| US-4837026-A | Transdermal and systemic preparation and method | THERAPEUTIC PATCH RESEARCH N.V. | 1989-06-06 | — | — | US | disclosed |
| US-4797151-A | Process for improving floral fertility | DEMIL EDMOND A (FR) | 1989-01-10 | — | — | US | disclosed |
| EP-0240554-A1 | TRANSDERMAL AND SYSTEMIC PREPARATION AND METHOD | RAJADHYAKSHA, Vithal J. (US) | 1987-10-14 | — | — | EP | disclosed |
| WO-1987001935-A1 | TRANSDERMAL AND SYSTEMIC PREPARATION AND METHOD | RAJADHYAKSHA VITHAL J | 1987-04-09 | — | — | WO | disclosed |
| CN-86101850-A | N, the manufacture method and the purposes of N '-dialkyl group guanidine radicals dipeptides | — | 1987-02-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170181947-A1 | MOISTURIZER AND COSMETIC CONTAINING SAME | PPT1, ACOX1, ALDH18A1 | ACE 2920/4885REN 3408/4885LMNA 4844/4885 |
| US-20250000948-A1 | SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | NPPA, BCAT1, ANPEP | ACE 684/4885REN 941/4885LMNA 3979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.